Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollander, Priscilla, Gupta, Alok K., Plodkowski, Raymond, Greenway, Frank, Bays, Harold, Burns, Colleen, Klassen, Preston, Fujioka, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836105/
https://www.ncbi.nlm.nih.gov/pubmed/24144653
http://dx.doi.org/10.2337/dc13-0234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836105/
https://www.ncbi.nlm.nih.gov/pubmed/24144653
http://dx.doi.org/10.2337/dc13-0234

Ejemplares similares